Although these anti-VEGF agents are superior to macular laser and a considerable proportion of patients improve visual acuity, the results of Diabetic Retinopathy Collaboration Network (DRCR.net) Protocol I and T studies show that persistent macular edema was seen in approximately 51–73% at 12 weeks and 32–66% after 24 weeks of regular anti-VEGF injections (5–8). The gene discussed is VEGFA; the disease is diabetic retinopathy.